IL6
Interleukin-6
Also known as: BSF2, HGF, HSF, IFNB2, IL-6, IL6_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P05231
- Gene
- IL6
- Ensembl
- ENSG00000136244
- Chromosome
- 7
- Canonical length
- 212 aa
- Protein class
- Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins
- Subcellular location
- Vesicles
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes a cytokine that functions in inflammation and the maturation of B cells. In addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is primarily produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including suspectibility to diabetes mellitus and systemic juvenile rheumatoid arthritis. Elevated levels of the encoded protein have been found in virus infections, including COVID-19 (disease caused by SARS-CoV-2). [provided by RefSeq, Aug 2020]
Canonical amino-acid sequenceUniProt
212 residues, UniProt reviewed canonical sequence.
>P05231|IL6
1 MNSFSTSAFG PVAFSLGLLL VLPAAFPAPV PPGEDSKDVA APHRQPLTSS ERIDKQIRYI
61 LDGISALRKE TCNKSNMCES SKEALAENNL NLPKMAEKDG CFQSGFNEET CLVKIITGLL
121 EFEVYLEYLQ NRFESSEEQA RAVQMSTKVL IQFLQKKAKN LDAITTPDPT TNASLLTKLQ
181 AQNQWLQDMT THLILRSFKE FLQSSLRALR QMLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.38
- Highest tissue expression
- 256 nTPM
Expression across tissuesHPA
Tissue
- urinary bladder: 256 nTPM
- adipose tissue: 188 nTPM
- lung: 141 nTPM
- heart muscle: 51 nTPM
- bone marrow: 43 nTPM
- blood vessel: 42 nTPM
Single-cell type
- endometrial luminal cells: 716 nCPM
- vascular smooth muscle cells: 566 nCPM
- vascular endothelial cells: 222 nCPM
- pericytes: 203 nCPM
- fibroblasts: 152 nCPM
- decidual stromal cells: 92 nCPM
Immune cell
- naive B-cell: 5.2 nTPM
- memory B-cell: 4.1 nTPM
- total PBMC: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- choroid plexus: 15 nTPM
- cerebral cortex: 5.2 nTPM
- pons: 3.8 nTPM
- thalamus: 2.9 nTPM
- white matter: 2.1 nTPM
- medulla oblongata: 2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IL6.
Disease | AllUniProt
Conditions IL6 is implicated in, by any mechanism.
- Rheumatoid arthritis systemic juvenile (RASJ) MIM:604302
Disease | AutoantibodyPubMed
Conditions in which antibodies against IL6 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for IL6 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
105 publications
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
2019 · N Engl J Med · RCR 23.6 · 496 citations - Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
2004 · Arthritis Rheum · RCR 12.9 · 610 citations - Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
2020 · Ann Oncol · RCR 11.7 · 236 citations - Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
2025 · Lancet Neurol · RCR 10.4 · 28 citations - Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.
1995 · J Exp Med · RCR 10.4 · 472 citations
Show 20 more of 105 total
- Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
2022 · Neurol Neuroimmunol Neuroinflamm · RCR 9.6 · 123 citations - Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
2021 · Nat Rev Neurol · RCR 7.1 · 112 citations - IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.
2008 · Proc Natl Acad Sci U S A · RCR 6.2 · 280 citations - New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD.
2021 · Neurol Neuroimmunol Neuroinflamm · RCR 6.1 · 84 citations - Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012).
2013 · J Clin Exp Hematop · RCR 5.8 · 157 citations - Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
2024 · Rheumatology (Oxford) · RCR 5.4 · 24 citations - Autoimmunity against melanoma differentiation-associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice.
2024 · Proc Natl Acad Sci U S A · RCR 4.5 · 22 citations - Life-Threatening MOG Antibody-Associated Hemorrhagic ADEM With Elevated CSF IL-6.
2024 · Neurol Neuroimmunol Neuroinflamm · RCR 3.8 · 18 citations - Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
2003 · J Rheumatol · RCR 3.5 · 170 citations - Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
2006 · Immunology · RCR 3.4 · 158 citations - Binding of cytokines to pharmaceutically prepared human immunoglobulin.
1993 · J Clin Invest · RCR 3.1 · 117 citations - Anti-interleukin-6 antibodies in normal human serum.
1991 · Scand J Immunol · RCR 3 · 112 citations - Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6.
2008 · J Immunol · RCR 2.9 · 149 citations - Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab.
2013 · Mod Rheumatol · RCR 2.6 · 78 citations - Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options.
2019 · Drugs · RCR 2.5 · 48 citations - Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness.
2023 · JCI Insight · RCR 2.5 · 24 citations - Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
2007 · Biol Pharm Bull · RCR 2.3 · 87 citations - Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus.
1993 · J Immunol · RCR 2.1 · 98 citations - Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice.
2023 · J Neuroimmunol · RCR 2.1 · 18 citations - Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series.
2020 · Mult Scler Relat Disord · RCR 2 · 36 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.75
- gnomAD pLI
- 0.32
- gnomAD missense Z
- 0
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- acute-phase response
- cell surface receptor signaling pathway via JAK-STAT
- cell surface receptor signaling pathway via STAT
- cellular response to hydrogen peroxide
- cellular response to lipopolysaccharide
- cellular response to virus
- cytokine-mediated signaling pathway
- defense response to Gram-negative bacterium
- defense response to Gram-positive bacterium
- defense response to virus
- endocrine pancreas development
- germinal center B cell differentiation
- glucose homeostasis
- hepatic immune response
- hepatocyte proliferation
- humoral immune response
- inflammatory response
- inflammatory response to wounding
- interleukin-6-mediated signaling pathway
- liver regeneration
- maintenance of blood-brain barrier
- monocyte chemotaxis
- negative regulation of apoptotic process
- negative regulation of bone resorption
- negative regulation of cell population proliferation
- negative regulation of chemokine production
- negative regulation of collagen biosynthetic process
- negative regulation of fat cell differentiation
- negative regulation of interleukin-1-mediated signaling pathway
- negative regulation of lipid storage
- negative regulation of neurogenesis
- negative regulation of primary miRNA processing
- neuron cellular homeostasis
- neuron projection development
- neutrophil apoptotic process
- neutrophil mediated immunity
- platelet activation
- positive regulation of acute inflammatory response
- positive regulation of apoptotic DNA fragmentation
- positive regulation of apoptotic process
- positive regulation of B cell activation
- positive regulation of cell population proliferation
- positive regulation of chemokine production
- positive regulation of cytokine production involved in inflammatory response
- positive regulation of DNA-templated transcription
- positive regulation of epithelial to mesenchymal transition
- positive regulation of extracellular matrix disassembly
- positive regulation of gene expression
- positive regulation of glial cell proliferation
- positive regulation of immunoglobulin production
- positive regulation of interleukin-1 beta production
- positive regulation of interleukin-10 production
- positive regulation of interleukin-17 production
- positive regulation of interleukin-21 production
- positive regulation of interleukin-6 production
- positive regulation of interleukin-8 production
- positive regulation of leukocyte adhesion to vascular endothelial cell
- positive regulation of leukocyte chemotaxis
- positive regulation of MAPK cascade
- positive regulation of miRNA transcription
- positive regulation of neuroinflammatory response
- positive regulation of osteoblast differentiation
- positive regulation of peptidyl-serine phosphorylation
- positive regulation of peptidyl-tyrosine phosphorylation
- positive regulation of platelet aggregation
- positive regulation of receptor signaling pathway via JAK-STAT
- positive regulation of receptor signaling pathway via STAT
- positive regulation of smooth muscle cell proliferation
- positive regulation of T cell proliferation
- positive regulation of T-helper 2 cell cytokine production
- positive regulation of transcription by RNA polymerase II
- positive regulation of translation
- positive regulation of tumor necrosis factor production
- positive regulation of type B pancreatic cell apoptotic process
- positive regulation of vascular endothelial growth factor production
- regulation of angiogenesis
- regulation of glucagon secretion
- regulation of insulin secretion
- regulation of microglial cell activation
- regulation of neuroinflammatory response
- regulation of vascular endothelial growth factor production
- response to activity
- response to glucocorticoid
- response to peptidoglycan
- T follicular helper cell differentiation
- T-helper 17 cell lineage commitment
- vascular endothelial growth factor production
- glucagon secretion
- regulation of astrocyte activation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Four-helical cytokine-like, core
- Interleukin-6/GCSF/MGF, conserved site
- Interleukin-6/GCSF/MGF
- Interleukin-6-like
- Interleukin-6/G-CSF/MGF family
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IL6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL6 as an antibody target. Whether an autoantibody or antibody against IL6 could matter depends on whether native IL6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL6 is annotated as secreted, so native IL6 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Source-annotated serology context
The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.
- In addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections.
Loading the interactive Seroatlas protein explorer...